Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05716477 · ClinicalTrials.gov registry record
Blood Test (Guardant Shield™) for Screening of Colorectal Cancer in Underserved Patients
A clinical trial, sponsored by Ohio State University Comprehensive Cancer Center.
- Completed
- Registry status
- 146
- Enrollment target
NCT05716477 is a clinical trial that has completed, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 146 participants.
The verdict
NCT05716477 has completed, sponsored by Ohio State University Comprehensive Cancer Center.
- COMPLETED
- Registry status
- 146 participants
- Enrollment target
Study Summary
This clinical trial evaluates the use of a blood test (Guardant Shield™) for colorectal cancer screening. Colorectal cancer is the third leading cancer and cause of death in the United States. Screening may help doctors find colorectal cancer early when it is easier to treat yet nearly a third of all people eligible for screening have never had a screening test performed. Currently, doctors use a stool- based test such as the fecal immunochemical test (FIT) and visual tests such as a colonoscopy. Blood based testing such as Guardant Shield™, may provide a quick and effective way to screen patients that are hard to reach or with limited access (underserved).
Interventions
- PROCEDURE Biospecimen Collection
- OTHER Survey Administration
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 146 participants |
| Start Date | 2022-12-23 |
| Est. Completion | 2024-11-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05716477
The ClinicalTrials.gov registry entry for NCT05716477 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 146 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ohio State University Comprehensive Cancer Center, which has 341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Biospecimen Collection is the first listed.
NCT05716477 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05716477 about?
NCT05716477 is a clinical study titled "Blood Test (Guardant Shield™) for Screening of Colorectal Cancer in Underserved Patients". This clinical trial evaluates the use of a blood test (Guardant Shield™) for colorectal cancer screening. Colorectal cancer is the third leading cancer and cause of death in the United States. Screening may help doctors find colorectal cancer early when it is easier to treat yet nearly a third of al...
What is the current status of trial NCT05716477?
This trial is currently completed. The enrollment target is 146 participants. The study started on 2022-12-23. Estimated completion is 2024-11-30.
What interventions are being tested in trial NCT05716477?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Survey Administration (OTHER).
Who is sponsoring clinical trial NCT05716477?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.